294 related articles for article (PubMed ID: 22388761)
21. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
[TBL] [Abstract][Full Text] [Related]
22. Current status of engineered T-cell therapy for synovial sarcoma.
Dallos M; Tap WD; D'Angelo SP
Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
[TBL] [Abstract][Full Text] [Related]
23. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
Endo M; de Graaff MA; Ingram DR; Lim S; Lev DC; Briaire-de Bruijn IH; Somaiah N; Bovée JV; Lazar AJ; Nielsen TO
Mod Pathol; 2015 Apr; 28(4):587-95. PubMed ID: 25412843
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.
Kakimoto T; Matsumine A; Kageyama S; Asanuma K; Matsubara T; Nakamura T; Iino T; Ikeda H; Shiku H; Sudo A
Oncol Lett; 2019 Apr; 17(4):3937-3943. PubMed ID: 30881511
[TBL] [Abstract][Full Text] [Related]
25. NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target.
Lai JP; Rosenberg AZ; Miettinen MM; Lee CC
Oncoimmunology; 2012 Nov; 1(8):1409-1410. PubMed ID: 23243610
[TBL] [Abstract][Full Text] [Related]
26. Distinction of endometrial stromal sarcomas from 'hemangiopericytomatous' tumors using a panel of immunohistochemical stains.
Bhargava R; Shia J; Hummer AJ; Thaler HT; Tornos C; Soslow RA
Mod Pathol; 2005 Jan; 18(1):40-7. PubMed ID: 15309019
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution.
Hornick JL; Fletcher CD
Am J Clin Pathol; 2002 Feb; 117(2):188-93. PubMed ID: 11865845
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.
Yoshikawa H; Rettig WJ; Lane JM; Takaoka K; Alderman E; Rup B; Rosen V; Healey JH; Huvos AG; Garin-Chesa P
Cancer; 1994 Aug; 74(3):842-7. PubMed ID: 8039112
[TBL] [Abstract][Full Text] [Related]
29. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
[TBL] [Abstract][Full Text] [Related]
30. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
31. Fluorescence in Situ Hybridization (FISH) for Differential Diagnosis of Soft Tissue Sarcomas.
Asif A; Mushtaq S; Hassan U; Akhtar N; Hussain M; Azam M; Qazi R
Asian Pac J Cancer Prev; 2018 Mar; 19(3):655-660. PubMed ID: 29580035
[TBL] [Abstract][Full Text] [Related]
32. Expression of MYCN in pediatric synovial sarcoma.
Somers GR; Zielenska M; Abdullah S; Sherman C; Chan S; Thorner PS
Mod Pathol; 2007 Jul; 20(7):734-41. PubMed ID: 17464317
[TBL] [Abstract][Full Text] [Related]
33. Three cases of synovial sarcoma of gastric wall: A case report and review of the literature.
Kuboyama Y; Yamada Y; Kohashi K; Toda Y; Kawakami K; Kitahara D; Nishiyama K; Hiraki Y; Oya M; Oda Y
Pathol Res Pract; 2021 Mar; 219():153352. PubMed ID: 33582394
[TBL] [Abstract][Full Text] [Related]
34. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics.
Foo WC; Cruise MW; Wick MR; Hornick JL
Am J Clin Pathol; 2011 Jun; 135(6):839-44. PubMed ID: 21571956
[TBL] [Abstract][Full Text] [Related]
36. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
Pollack SM
Expert Rev Vaccines; 2018 Feb; 17(2):107-114. PubMed ID: 29280411
[TBL] [Abstract][Full Text] [Related]
37. Synovial Sarcoma of the Gastrointestinal Tract.
Ortiz Requena D; Longacre TA; Rosenberg AE; Velez Torres JM; Yanchenko N; Garcia-Buitrago MT; Voltaggio L; Montgomery EA
Mod Pathol; 2024 Jan; 37(1):100383. PubMed ID: 37972927
[TBL] [Abstract][Full Text] [Related]
38. The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis.
Jones KB; Barrott JJ; Xie M; Haldar M; Jin H; Zhu JF; Monument MJ; Mosbruger TL; Langer EM; Randall RL; Wilson RK; Cairns BR; Ding L; Capecchi MR
Oncogene; 2016 Sep; 35(38):5021-32. PubMed ID: 26947017
[TBL] [Abstract][Full Text] [Related]
39. HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor.
Hui P; Li N; Johnson C; De Wever I; Sciot R; Manfioletti G; Tallini G
Mod Pathol; 2005 Nov; 18(11):1519-26. PubMed ID: 16056249
[TBL] [Abstract][Full Text] [Related]
40. A minute primary gastric synovial sarcoma with ulcer: a case report.
Yoshiyasu K; Kono H; Hojo Y; Ishida Y; Tamura A; Nakai K; Oshima T; Miwa H; Shinohara H; Hirota S
Diagn Pathol; 2021 Dec; 16(1):115. PubMed ID: 34895269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
